Cimlanod, a Second-Generation Nitroxyl Donor, in Heart Failure with Reduced Ejection Fraction: A Meta-Analysis of Hemodynamic Efficacy and Safety Profile
Cimlanod, a Second-Generation Nitroxyl Donor, in Heart Failure with Reduced Ejection Fraction: A Meta-Analysis of Hemodynamic Efficacy and Safety Profile
Juliana Giorgi, HEMANK WALIA, Salomon Chamay, Mrunalini Dandamudi et al.
Journal
American Journal of Cardiovascular Drugs
Topics
Transplantation: Methods and Outcomes
article
Cimlanod, a Second-Generation Nitroxyl Donor, in Heart Failure with Reduced Ejection Fraction: A Meta-Analysis of Hemodynamic Efficacy and Safety Profile
Juliana Giorgi, HEMANK WALIA, Salomon Chamay, Mrunalini Dandamudi, M. Samaniego, Giang Son Arrighini, V Q T Ho
article en
Abstract
No abstract available for this paper.
Publication Tag
American Journal of Cardiovascular Drugs
Institutions
University of Debrecen (HU), Montefiore Medical Center (US), Duke University (US), Universidad Autónoma Metropolitana (MX), Hospital Israelita Albert Einstein (BR), Pontificia Universidad Católica Argentina (AR), Advocate Illinois Masonic Medical Center (US), Hospital Sírio-Libanês (BR), Atlantic Health System (US), University of Bologna (IT)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Cimlanod, a Second-Generation Nitroxyl Donor, in Heart Failure with Reduced Ejection Fraction: A Meta-Analysis of Hemodynamic Efficacy and Safety Profile — Juliana Giorgi, HEMANK WALIA, et al. · American Journal of Cardiovascular Drugs (2026) | TGRS Research Map | TGRS